

High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study

Renato Quispe, MD, MHS; Erin D. Michos, MD, MHS; Seth S. Martin, MD, MHS; Rishi Puri, MBBS, PhD; Peter P. Toth, MD, PhD; Jassim Al Suwaidi, MD; Maciej Banach, MD, PhD; Salim S. Virani, MD, PhD; Roger S. Blumenthal, MD; Steven R. Jones, MD; Mohamed B. Elshazly, MD

Background—Inflammation is an independent causal risk factor for atherosclerotic cardiovascular diseases (ASCVDs). However, whether hsCRP (high-sensitivity C-reactive protein) is prognostic across various levels of atherogenic lipid measures such as low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B and total cholesterol/high-density lipoprotein cholesterol in primary prevention is unknown.

Methods and Results—We studied 9748 ARIC (Atherosclerosis Risk in Communities) study participants who were free of ASCVD at baseline (visit 4, 1996–1998) and had measurements of lipids, apolipoprotein B, and hsCRP. We used multivariable adjusted Cox models to estimate the risk of incident ASCVD events associated with hsCRP levels (less than/greater than or equal to median) in individuals where triple lipid measures combined (low-density lipoprotein cholesterol + non-high-density lipoprotein cholesterol + apolipoprotein B) or quadruple measures combined [triple + total cholesterol/high-density lipoprotein cholesterol] were less than versus greater than or equal to median cut points. Mean age of participants was 62.6 ± 5.6 years; 59% women, 22% black. There were 1574 ASCVD events over median (interquartile range) follow-up of 18.4 (12.8–19.5) years, and discordance between hsCRP and lipid measures was prevalent in 50% of the population. hsCRP greater than or equal to median (2.4 mg/L), compared with less than median, was associated with an increased risk of ASCVD in individuals with less than median levels of the triple (adjusted hazard ratio, 1.33; 95% CI, 1.09–1.60) and quadruple (adjusted hazard ratio, 1.47; 95% CI, 1.18–1.85) lipid measures. Such increased risk was consistent among individuals with low (<7.5%) or high ($\geq 7.5\%$) estimated risk by the pooled cohort equation. There were no interactions by sex, diabetes mellitus, or statin use.

Conclusions—Our findings suggest that inflammation is independently associated with ASCVD regardless of atherogenic lipid levels and pooled cohort equation risk score in individuals without known ASCVD. (*J Am Heart Assoc.* 2020;9:e013600. DOI: 10.1161/JAHA.119.013600.)

Key Words: apolipoprotein • C-reactive protein • low density lipoprotein cholesterol • primary prevention

Accumulating evidence from the past 2 decades suggests that inflammation plays a causal role, independent of lipoprotein levels, in the development of atherosclerotic cardiovascular disease (ASCVD; “inflammation hypothesis”).¹

Early observations^{2,3} led to the landmark JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) trial, which showed that rosuvastatin therapy reduced ASCVD events in a primary prevention

From the Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD (R.Q., E.D.M., S.S.M., R.S.B., M.B.E.); Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH (R.P.); Department of Preventive Cardiology, CGH Medical Center, Sterling, IL (P.P.T.); University of Illinois College of Medicine, Peoria, IL (P.P.T.); Division of Cardiology, Department of Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar (J.A.S., M.B.E.); Department of Cardiology, Heart Hospital, HMC, Doha, Qatar (J.A.S., M.B.E.); Department of Hypertension, Medical University of Lodz, Lodz, Poland (M.B.); Michael E. DeBakey Veterans Affairs Medical Center and Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX (S.S.V.).

Accompanying Tables S1 through S7 and Figures S1 through S4 are available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.013600>

Correspondence to: Mohamed B. Elshazly, MD, Department of Cardiovascular Medicine, Weill Cornell Medicine—Qatar, Education City, PO Box 24144, Doha, Qatar. E-mail: mes2015@qatar-med.cornell.edu

Received June 12, 2019; accepted December 4, 2019.

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Clinical Perspective

What Is New?

- In a primary prevention US cohort, discordance between hsCRP (high-sensitivity C-reactive protein) levels, a marker of subclinical inflammation, and atherogenic lipids was common using different discordance definitions ($\approx 50\%$ using the median cut points definition), and elevated hsCRP consistently enhanced atherosclerotic cardiovascular disease risk in individuals regardless of their baseline absolute risk determined by various atherogenic lipid measures and the pooled cohort equation score.
- Individuals with favorable atherogenic lipid levels (low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B, and total cholesterol/high-density lipoprotein cholesterol all relatively low), but a discordantly elevated hsCRP level, had a 30% to 60% greater relative risk of developing atherosclerotic cardiovascular disease events over a long period of time (median follow-up ≈ 18 years) compared with those with lower hsCRP; individuals with unfavorable atherogenic lipid levels (all relatively high) and an elevated hsCRP level had a similarly higher atherosclerotic cardiovascular disease risk.
- Individuals with higher levels of hsCRP also had an independently enhanced risk of incident heart failure and all-cause death compared with those with lower hsCRP levels.

What Are the Clinical Implications?

- hsCRP levels should be regularly considered along with atherogenic lipid measures in a holistic and personalized risk-based approach to atherosclerotic cardiovascular disease risk assessment and primary prevention.
- Elevated hsCRP levels can serve as a risk enhancer irrespective of baseline absolute risk determined by various atherogenic lipid measures and the pooled cohort equation risk score.
- Individuals with elevated hsCRP may additionally benefit from an intensive anti-inflammatory lifestyle and also possibly from anti-inflammatory medications such as high-intensity statin therapy or colchicine; however, this requires further prospective validation in clinical trials.

population with low-density lipoprotein cholesterol (LDL-C) < 130 mg/dL but an elevated hsCRP (high-sensitivity C-reactive protein) ≥ 2 mg/L, a marker of subclinical inflammation.⁴ However, it remained unclear whether the observed benefits in JUPITER were directly related to reduction of hsCRP, LDL-C, or both, or other atherogenic lipoproteins. Further, post hoc analyses from multiple lipid-lowering trials have shown that individuals reaching dual low LDL-C and hsCRP targets had superior outcomes compared with those who only reached an LDL-C target.^{5,6} Validation for the role of

inflammation in ASCVD was strengthened even more recently after the CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed reduction in recurrent cardiovascular events with canakinumab treatment,⁷ especially among those who achieved hsCRP < 2 mg/L at 3 months on therapy.⁸

ASCVD events are known to occur more frequently among individuals with relatively low LDL-C levels who have discordantly elevated levels of atherogenic lipid parameters such as non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B,⁹ and the total cholesterol (TC) to HDL-C ratio (TC/HDL-C).^{10,11} Given that discordance between these various atherogenic lipid measures is common and clinically relevant, one way to isolate the independent contribution of heightened inflammation to atherosclerosis is to study whether hsCRP levels can provide additional information in situations when these atherogenic lipid and lipoprotein levels are all concordantly favorable or unfavorable. In a large, predominantly biracial population of US adults without known ASCVD, we aimed to evaluate whether hsCRP can provide additional long-term prognostic information regarding risk of ASCVD independent of lipid and lipoprotein levels.

Methods

The data, analytic methods, and study materials can be made available to other researchers upon request, for purposes of reproducing the results, in accordance with ARIC (Atherosclerosis Risk in Communities) study policies.

Study Population

The ARIC study is a multicenter, prospective cohort of 15 792 middle-aged men and women, established in 1987 from the following 4 communities in the United States: suburban Minneapolis, Minnesota; Forsyth County, North Carolina; Washington County, Maryland; and Jackson, Mississippi. The ARIC study design has been previously reported.¹² Individuals aged 45 to 64 years were enrolled between 1987 and 1989 as part of the baseline (visit 1) clinic examination. For the present study, we used visit 4 (1996–1998) as baseline given that lipid panel, apolipoprotein B and hsCRP were all measured at that visit. Participants also completed questionnaires, underwent a physical exam, and had blood samples collected and stored. Additionally, participants or their proxies were contacted by phone annually to obtain information on occurrence of ASCVD events and their vital status.

For the present analysis, we had the following exclusion criteria: (1) those with prevalent ASCVD at baseline ($n=983$); (2) those who were neither black nor white, or

blacks from Minnesota and Maryland centers (n=69), given that small numbers did not allow for adjustment by race/center groups; and (3) those missing values for lipid or hsCRP variables (n=856). Our final sample included 9748 participants.

Institutional review boards at all participating institutions approved the ARIC study. All participants provided written informed consent at each study visit.

Lipid- and hsCRP-Based Categories

Fasting blood lipid levels were measured according to standard procedures.¹² Plasma TC and triglycerides were determined by enzymatic methods, and HDL-C was measured after dextran-magnesium precipitation (<https://www2.csc.unc.edu/aric/cohort-manuals>). Apolipoprotein B was measured for all participants using World Health Organization/International Federation of Clinical Chemistry standardized reference materials.

For this study, we estimated LDL-C using our novel Hopkins-Martin estimation method, which uses 1 of 180 different factors for the ratio of triglycerides to very-low-density lipoprotein cholesterol (VLDL-C) according to non-HDL-C and TG levels¹³ and has been externally validated by groups inside and outside the United States.^{14–16} In addition to LDL-C, we calculated the TC/HDL-C ratio and non-HDL-C (TC minus HDL-C).

We performed 3 analyses based on 3 sets of cut points (a, b and c) for our atherogenic lipid measures: (a) median cut points; (b) JUPITER cut points: LDL-C (130 mg/dL) and non-HDL-C (160 mg/dL), whereas apolipoprotein B (102 mg/dL) and TC/HDL-C (4.4) cut points were determined from the ARIC percentile-equivalent values (57th percentile) to LDL-C 130 mg/dL; (c) high-risk cut points: LDL-C (100 mg/dL) and non-HDL-C (130 mg/dL), high-risk targets recommended by international guidelines,^{17,18} whereas apolipoprotein B (80 mg/dL) and TC/HDL-C (3.1) cut points were determined from ARIC percentile-equivalent values (21st percentile). HDL-C cut points used were median (40 mg/dL) for (a) and 50 mg/dL for (b) and (c). In addition, we created 2 hsCRP categories defined by less than and greater than or equal to median (2.4 mg/L) for the analysis in (a), and less than and ≥ 2 mg/L for the analyses in (b) and (c).

Using each set of lipid group cut points (a, b, and c), we compared individuals with hsCRP less than cutpoint to those greater than or equal to cut point in the following groups:

1. Triple lipid measures combined: [LDL-C AND non-HDL-C AND apolipoprotein B] less than cut point versus [LDL-C AND non-HDL-C AND apolipoprotein B] greater than or equal to cut point

2. Quadruple lipid measures combined: [LDL-C AND non-HDL-C AND apolipoprotein B AND TC/HDL-C] less than cut point versus [LDL-C AND non-HDL-C AND apolipoprotein B AND TC/HDL-C] greater than or equal to cut point

For example, we stratified participants with triple lipid measures (LDL-C AND non-HDL-C AND apolipoprotein B) less than median levels into those with hsCRP less than median (concordant) versus greater than or equal to median (discordant) and did the same in individuals with triple levels greater than or equal to median [(hsCRP less than median (discordant) and hsCRP greater than or equal to median (concordant))].

We also performed more extensive discordance analyses of hsCRP less than/greater than or equal to cut points across cut points of LDL-C only followed by the gradual addition of other lipid and lipoprotein cut points in the following order: non-HDL-C, apolipoprotein B, TC/HDL-C, and HDL-C.

Other Covariates

Demographics (age, sex, race/center, education, etc) and cardiovascular risk factors (smoking status, physical activity assessed using a modified interviewer-administered Baecke Questionnaire, diabetes mellitus, hypertension) were obtained from history, physical examination, and laboratory data at baseline (visit 4). Smoking status was categorized as never/former and current smoker. Body mass index was calculated from measured height and weight. Diabetes mellitus was defined as a fasting (≥ 8 hours) serum glucose ≥ 126 mg/dL, nonfasting glucose ≥ 200 mg/dL, self-reported physician diagnosis of diabetes mellitus, or reported use of hypoglycemic agents. Blood pressure was measured 3 times, and the mean of the second and third measurements was used. Use of lipid-lowering and antihypertensive medications were self-reported.

Outcomes

The primary outcome was incident ASCVD determined from hospital discharge codes or death certificates. Incident ASCVD was defined as definite or probable myocardial infarction, definite coronary death, and definite or probable stroke (sudden or rapid onset of neurological symptoms that lasted for 24 hours or led to death in the absence of another cause).^{19–21} Additionally, ARIC investigators conducted continuous surveillance for all cardiovascular disease-related hospitalizations and deaths. All ASCVD events were adjudicated by the ARIC study investigators. Study participants contributed follow-up time from the date of the participant's

Table 1. Baseline Characteristics in Concordant and Discordant Groups by Medians: The ARIC Study

| | Overall Population | Four Lipids Less Than Median | | | Four Lipids Greater Than or Equal to Median | | |
|--------------------------------------|---------------------|------------------------------|-------------------|---------|---|---------------------|---------|
| | | hsCRP < Median | hsCRP ≥ Median | P Value | hsCRP < Median | hsCRP ≥ Median | P Value |
| Age, y | 62 (58–67) | 62 (57–67) | 62 (58–67) | 0.72 | 62.5 (58–67) | 62 (58–67) | 0.73 |
| Female, n (%) | 5765 (59.1) | 932 (56.1) | 1138 (78.0) | <0.0001 | 611 (41.9) | 1021 (63.1) | <0.0001 |
| Race/center, n (%) | | | | <0.0001 | | | <0.0001 |
| Minneapolis, MN, Whites | 2713 (28.0) | 479 (29.1) | 335 (23.1) | | 455 (31.4) | 410 (25.5) | |
| Washington County, MD, Whites | 2658 (27.5) | 406 (24.7) | 313 (21.6) | | 449 (31.0) | 512 (31.8) | |
| Forsyth County, NC, Whites | 2180 (22.5) | 408 (24.8) | 324 (22.4) | | 339 (23.4) | 335 (20.8) | |
| Forsyth County, NC, Blacks | 217 (2.2) | 39 (2.4) | 55 (3.8) | | 15 (1.0) | 30 (1.9) | |
| Jackson, MS, Blacks | 1916 (19.8) | 315 (19.1) | 420 (29.0) | | 189 (13.1) | 324 (20.1) | |
| Body mass index, kg/m ² | 28.0 (24.9–31.6) | 25.5 (22.8–28.4) | 28.5 (24.8–33.4) | <0.001 | 27.6 (25.1–30.4) | 30.2 (27.1–34.2) | <0.0001 |
| LDL-C, mg/dL | 123.6 (103.3–145.4) | 97.8 (84.0–109.0) | 97.4 (82.8–108.4) | 0.29 | 152.6 (139.1–168.4) | 151.9 (139.4–169.5) | 0.81 |
| Non-HDL-C, mg/dL | 149 (126–173) | 116 (102–128) | 118 (103–130) | 0.06 | 182 (167–200) | 184 (169–204) | 0.035 |
| TC/HDL-C | 4.2 (3.3–5.2) | 3.0 (2.5–3.5) | 3.1 (2.6–3.6) | 0.06 | 5.4 (4.8–6.1) | 5.6 (4.9–6.4) | 0.0001 |
| Apolipoprotein B, mg/dL | 98.1 (82.8–113.7) | 78.2 (69.8–85.8) | 79.6 (70.6–87.6) | 0.05 | 117.3 (108.6–129.9) | 119.6 (109.8–132.5) | 0.001 |
| HDL-C, mg/dL | 48 (39–60) | 58 (48–70) | 57 (47–69) | 0.12 | 42 (36–47) | 41 (35–46) | 0.001 |
| hsCRP, mg/L | 2.4 (1.1–5.4) | 0.9 (0.5–1.5) | 5.7 (3.7–8.9) | <0.0001 | 1.2 (0.8–1.7) | 5.3 (3.7–8.4) | <0.0001 |
| Lipid-lowering medication use, n (%) | 1104 (11.4) | 138 (8.3) | 90 (6.2) | 0.022 | 133 (9.1) | 125 (7.8) | 0.171 |
| Current smoker, n (%) | 1403 (14.5) | 233 (14.1) | 218 (15.0) | 0.471 | 161 (11.1) | 311 (19.2) | <0.0001 |
| Systolic blood pressure, mm Hg | 125 (114–138) | 122 (111–135) | 126 (114–140) | <0.0001 | 124 (113–137) | 128 (117–141) | <0.0001 |
| Antihypertensive medications, n (%) | 3866 (39.7) | 598 (36.2) | 744 (51.2) | <0.0001 | 589 (40.5) | 838 (51.9) | <0.0001 |
| Diabetes mellitus, n (%) | 1495 (15.4) | 151 (9.2) | 211 (14.6) | <0.0001 | 186 (12.8) | 375 (23.2) | <0.0001 |
| 10-y ASCVD risk | 8.0 (3.3–14.9) | 6.0 (2.3–11.9) | 5.8 (2.3–11.6) | 0.8966 | 10.5 (5.7–17.5) | 9.7 (4.1–18.5) | 0.0742 |

Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apolipoprotein B: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L. Continuous variables are reported as median (25th–75th percentile). Medians and means were compared using Kruskal-Wallis and chi-squared test, respectively. International System of Units conversion factors: To convert total, LDL-C, and HDL-C to mmol/L, multiply by 0.0249. To convert triglycerides to mmol/L, multiply by 0.0113. ARIC indicates Atherosclerosis Risk in Communities; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

baseline visit until the date of incident ASCVD event, death, loss to follow-up, or the end of follow-up (December 31, 2016), whichever came first.

Secondary outcomes included incident heart failure (HF) and total mortality. Incident HF, defined as the first hospitalization or death related to HF occurring after visit

Table 2. Hazard Ratios (95% CI) for ASCVD Events Across Concordant/Discordant Groups by Medians: The ARIC Study

| Lipid Target Groups | hsCRP | n ASCVD Events/n Individuals | Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 3 HR (95% CI) | Model 4 HR (95% CI) |
|---------------------------|----------|------------------------------|---------------------|---------------------|---------------------|---------------------|
| Triple lipids < median | < median | 237/2060 | REF | REF | REF | REF |
| (n=3938) | ≥ median | 290/1878 | 1.57 (1.31–1.88) | 1.46 (1.19–1.78) | 1.42 (1.16–1.74) | 1.42 (1.16–1.73) |
| Triple lipids ≥ median | < median | 315/1954 | REF | REF | REF | REF |
| (n=4064) | ≥ median | 442/2110 | 1.56 (1.34–1.81) | 1.33 (1.13–1.57) | 1.32 (1.12–1.56) | 1.31 (1.11–1.55) |
| Quadruple lipids < median | < median | 171/1660 | REF | REF | REF | N/A |
| (n=3120) | ≥ median | 207/1460 | 1.62 (1.31–2.01) | 1.60 (1.26–2.02) | 1.56 (1.23–1.98) | N/A |
| Quadruple lipids ≥ median | < median | 257/1460 | REF | REF | REF | N/A |
| (n=3079) | ≥ median | 362/1619 | 1.52 (1.29–1.79) | 1.30 (1.08–1.56) | 1.29 (1.08–1.55) | N/A |

hsCRP less than median groups are reference. Triple lipids: LDL-C + non-HDL-C + apolipoprotein B. Quadruple lipids: LDL-C + non-HDL-C + apolipoprotein B + TC/HDL-C. Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apolipoprotein B: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L. Model 1: adjusted for age, sex, race/center. Model 2: Model 1 + physical activity + smoking status + body mass index + systolic blood pressure + treatment for hypertension + diabetes mellitus + lipid-lowering medication use. Model 3: Model 2 + log-triglycerides. Model 4: Model 3 + log-HDL-C. International System of Units conversion factors: To convert total, LDL-C, and HDL-C to mmol/L, multiply by 0.0249. To convert triglycerides to mmol/L, multiply by 0.0113. ARIC indicates Atherosclerosis Risk in Communities; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; N/A indicates not applicable; TC, total cholesterol.

4 (baseline) until end of follow-up. Hospitalized HF was determined from hospital discharge codes and HF deaths from the underlying cause assigned on the death certificate. Total mortality was obtained subsequent to visit 4 until the end of follow-up.

Statistical Analyses

Baseline characteristics of the study population by lipids and hsCRP concordance/discordance categories were described using medians (25th–75th percentiles) for continuous and proportions for categorical variables. Comparisons were performed using Kruskal–Wallis test and chi-square, respectively, between hsCRP categories within lipid less than cut point and greater than or equal to cut point groups, separately.

For our prospective analysis we constructed 4 Cox proportional hazard models. Model 1 was adjusted by age, sex, and race/center groups. Model 2 was additionally adjusted by physical activity, smoking status, body mass index, systolic blood pressure, treatment for hypertension, diabetes mellitus, and lipid-lowering medication use. Model 3 was additionally adjusted by log-transformed triglycerides. Model 4 was additionally adjusted by log-HDL-C for lipid-based groups 1 to 3 only. Further, we constructed unadjusted Kaplan–Meier curves for all lipids and hsCRP concordance/discordance groups.

Additionally, all primary analyses were stratified by risk categories defined a priori, estimated by the pooled cohort equations (PCE) (low: <7.5%, high: ≥7.5%).²² Finally, we evaluated effect modification (interaction) by sex, PCE risk categories, statin use, and diabetes mellitus, according to sample sizes shown in Tables 1 and 2.

Results

Among the 9748 included participants, the mean age at baseline was 62.5±5.6 years; 59% were women, and 22% were black. At the baseline visit, median levels were LDL-C, 123 mg/dL; non-HDL-C, 149 mg/dL; apolipoprotein B: 98 mg/dL; TC/HDL, 4.2; HDL-C, 40 mg/dL; hsCRP, 2.4 mg/L. The proportion of hsCRP discordance with lipid measures was ≈50% within all lipid groups (Figures S1 and S2). For example, among those with a more favorable lipid profile (quadruple lipid measures less than median), 47% had a discordantly elevated hsCRP greater than or equal to median.

Baseline Characteristics

Table 1 shows the baseline characteristics of study population by concordant/discordant groups when combining the quadruple atherogenic lipid measures versus hsCRP. Among those with a favorable lipid profile (quadruple lipid measures combined less than median), individuals with hsCRP greater than or equal to median were predominantly women, had a higher body mass index, and had a greater proportion of diabetes mellitus and hypertension ($P<0.001$) but similar 10-year PCE ASCVD risk, compared with those with hsCRP <median. A comparable pattern was found among those with an unfavorable lipid profile (quadruple lipid measures combined greater than or equal to median).

Discordance Using Median Cutpoints

Over a median follow-up of 18.4 years (interquartile range, 12.8–19.5), there were 1574 incident ASCVD events (713




Figure 1. Kaplan–Meier curves for event-free survival of atherosclerotic cardiovascular events by hsCRP less than and greater than or equal to median among individuals with triple (A), quadruple (B) lipid measures less than median (left) and greater than or equal to median (right). HDL-C indicates high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

had definite/probable myocardial infarction, 304 had coronary death, 557 had definite/probable stroke). Figures 1 and 2 show Kaplan–Meier curves for hsCRP greater than or equal to cut points versus hsCRP less than cut points across various lipid groups. Table 2 shows the prospective analysis for hazard of incident ASCVD by hsCRP level (less than/greater than or equal to median) across triple and quadruple lipid measures stratified by less than/greater than or equal to median cut points. We observed a significant independent $\approx 30\%$ to 60% increase in ASCVD risk in individuals with hsCRP greater than or equal to median versus less than median regardless of levels of triple or quadruple lipid measures even after adjusting for multiple factors known to be associated with ASCVD and log-triglyceride levels (Table 2). Of note, this increased risk of ASCVD was similar in our supplementary analysis across all lipid groups starting from discordance

with LDL-C only to the gradual addition of other lipid measures (Table S1).

Further, we found that the increased ASCVD risk associated with elevated hsCRP regardless of atherogenic lipid levels was consistent among individuals with low ($<7.5\%$) or high ($\geq 7.5\%$) 10-year estimated risk by the PCE (Table 3 and Table S2).

Additionally, we observed consistent results when using incident heart failure (Figure S3, Table 4), total mortality (Figure S4, Table 5) and coronary death as outcomes (Table 6, Table S3).

Discordance Using JUPITER Cut Points

Table 7 shows hazards of incident ASCVD by hsCRP level ($</\geq 2$ mg/L) across the same lipid groups stratified by JUPITER cut points. We observed an independent increase in




Figure 2. Kaplan–Meier curves for event-free survival of atherosclerotic cardiovascular events by hsCRP less than and ≥ 2 mg/L among individuals with triple (A), quadruple (B) measures less than JUPITER cut points (left) and greater than or equal to JUPITER cut points (right). HDL-C indicates high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; JUPITER, Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.

ASCVD risk of about 28% to 41% in individuals with hsCRP ≥ 2 versus < 2 mg/L across (less than and greater than or equal to JUPITER cut points) of triple and quadruple lipid groups (Table 6) as well as other lipid groups (Table S4). Furthermore, we reproduced our analysis using several hsCRP categories (< 1 , 1–2, 2–3, and ≥ 3 mg/L) and found a stepwise increase in ASCVD risk at higher hsCRP levels (Table S5).

Discordance Using High-Risk Cut Points

Finally, when using high-risk cut points equivalent to LDL-C 100 mg/dL, we observed a similar effect size of 25% to 40% increased risk in individuals with hsCRP ≥ 2 versus < 2 mg/L, although it did not reach statistical significance (defined as $P > 0.05$) in groups with smaller sample size (Table S6).

Of note, there was no evidence for interaction by sex, statin use, or diabetes mellitus when using medians, JUPITER,

or high-risk targets. Finally, we used a time-varying analysis across multiple visits, and our results did not change (Table S7).

Discussion

In a large biracial cohort of US adults without known ASCVD at baseline and followed for > 18 years, individuals with a higher degree of inflammation, determined by hsCRP levels, had heightened risk of ASCVD events, incident HF, and all-cause death across various levels of atherogenic lipid measures. Approximately 1 in 2 ASCVD-free individuals with a more favorable lipid pattern (all atherogenic lipid measures less than median) had an elevated hsCRP (greater than or equal to median), which was associated with a 56% increased risk of ASCVD at ≈ 18 years of follow-up. This finding was consistent across categories of estimated global ASCVD risk

Table 3. Hazard Ratios (95% CI) for ASCVD Events Across Concordant/Discordant Groups by Medians, Grouped Using the Pooled Cohort Equation Risk Score: The ARIC Study

| Lipid Target Groups | hsCRP | Low Risk (<7.5%) | | High Risk (≥7.5%) | |
|---------------------------|----------|--------------------------------|------------------|--------------------------------|------------------|
| | | ASCVD Events, n/Individuals, n | HR (95% CI) | ASCVD Events, n/Individuals, n | HR (95% CI) |
| Triple lipids < median | < median | 80/1091 | REF | 154/948 | REF |
| (n=3938) | ≥ median | 125/1010 | 1.79 (1.35–2.37) | 162/851 | 1.27 (1.02–1.59) |
| Triple lipids ≥ median | < median | 75/779 | REF | 238/1162 | REF |
| (n=4064) | ≥ median | 134/931 | 1.57 (1.18–2.08) | 304/1169 | 1.42 (1.20–1.69) |
| Quadruple lipids < median | < median | 65/955 | REF | 104/688 | REF |
| (n=3120) | ≥ median | 96/857 | 1.73 (1.26–2.37) | 110/591 | 1.35 (1.03–1.77) |
| Quadruple lipids ≥ median | < median | 56/507 | REF | 199/942 | REF |
| (n=3079) | ≥ median | 101/651 | 1.47 (1.06–2.04) | 258/962 | 1.42 (1.18–1.71) |

hsCRP <median groups are reference. Triple lipids: LDL-C + non-HDL-C + apolipoprotein B. Quadruple lipids: LDL-C + non-HDL-C + apolipoprotein B + TC/HDL-C. Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apolipoprotein B: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L. Models adjusted for lipid-lowering medication use. International System of Units conversion factors: To convert total, LDL-C, and HDL-C to mmol/L, multiply by 0.0249. To convert triglycerides to mmol/L, multiply by 0.0113. ARIC indicates Atherosclerosis Risk in Communities; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; N/A indicates not applicable; TC, total cholesterol.

by the PCE, supporting the notion that hsCRP may serve as a risk enhancer regardless of lipid levels and estimated global ASCVD risk. Future studies should examine the potential value of anti-inflammatory interventions (through lifestyle or novel pharmaceuticals), beyond lowering atherogenic lipids, in the primary prevention of ASCVD.

Subclinical Inflammation in the Current Era of ASCVD Risk Assessment in Primary Prevention

The current trend in primary prevention is to assess individual short-term (ie, 10-year) ASCVD risk using scores that

incorporate clinical variables and cholesterol measurements.^{17,18,22,23} Because of the significant role of inflammation in atherogenesis, efforts were made to assess the utility of markers of subclinical inflammation, such as hsCRP, to improve risk assessment when considered in addition to traditional risk assessment tools.^{24–27} The most recent Multi-Society American Heart Association/American College of Cardiology cholesterol treatment guideline published in 2018²⁸ gives a class IIb recommendation for using moderate-intensity statin therapy in borderline risk (PCE score 5 to <7.5%) individuals with an hsCRP level ≥2 mg/L, considered as an ASCVD risk enhancer. In addition, the latest ESC guideline states that inflammation modifies the

Table 4. Hazard Ratios (95%CI) for Incident Heart Failure Across Concordant/Discordant Groups by Medians: The ARIC Study

| Lipid Target Groups | hsCRP | Incident HF, n/Individuals, n | Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 3 HR (95% CI) | Model 4 HR (95% CI) |
|---------------------------|----------|-------------------------------|---------------------|---------------------|---------------------|---------------------|
| Triple lipids < median | < median | 268/2044 | REF | REF | REF | REF |
| (n=3888) | ≥ median | 360/1844 | 1.74 (1.48–2.05) | 1.28 (1.07–1.53) | 1.26 (1.05–1.51) | 1.26 (1.05–1.52) |
| Triple lipids ≥ median | < median | 243/1940 | REF | REF | REF | REF |
| (n=4024) | ≥ median | 424/2084 | 1.89 (1.61–2.22) | 1.36 (1.14–1.63) | 1.36 (1.14–1.63) | 1.37 (1.14–1.63) |
| Quadruple lipids < median | < median | 204/1647 | REF | REF | REF | N/A |
| (n=3086) | ≥ median | 258/1439 | 1.70 (1.40–2.07) | 1.35 (1.09–1.66) | 1.33 (1.07–1.64) | N/A |
| Quadruple lipids ≥ median | < median | 182/1449 | REF | REF | REF | N/A |
| (n=3048) | ≥ median | 336/1599 | 1.95 (1.62–2.35) | 1.38 (1.13–1.69) | 1.38 (1.13–1.69) | N/A |

Individuals with prevalent heart failure at visit 4 were excluded from analysis (n=271). hsCRP less than median groups are reference. Triple lipids: LDL-C + non-HDL-C + apolipoprotein B. Quadruple lipids: LDL-C + non-HDL-C + apolipoprotein B + TC/HDL-C. Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apolipoprotein B: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L. Model 1: adjusted for age, sex, race/center. Model 2: Model 1 + physical activity + smoking status + body mass index + systolic blood pressure + treatment for hypertension + diabetes mellitus + lipid-lowering medication use. Model 3: Model 2 + log-triglycerides. Model 4: Model 3 + log-HDL-C. International System of Units conversion factors: To convert total, LDL-C, and HDL-C to mmol/L, multiply by 0.0249. To convert triglycerides to mmol/L, multiply by 0.0113. ARIC indicates Atherosclerosis Risk in Communities; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; N/A indicates not applicable; TC, total cholesterol.

Table 5. Hazard Ratios (95% CI) for All-Cause Mortality Across Concordant/Discordant Groups by Medians: The ARIC Study

| Lipid Target Groups | hsCRP | Deaths, n/Individuals, n | Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 3 HR (95% CI) | Model 4 HR (95% CI) |
|---------------------------|----------|--------------------------|---------------------|---------------------|---------------------|---------------------|
| Triple lipids < median | < median | 699/2060 | REF | REF | REF | REF |
| (n=3938) | ≥ median | 743/1878 | 1.41 (1.26–1.57) | 1.29 (1.14–1.45) | 1.28 (1.14–1.44) | 1.28 (1.14–1.45) |
| Triple lipids ≥ median | < median | 605/1954 | REF | REF | REF | REF |
| (n=4064) | ≥ median | 815/2110 | 1.47 (1.32–1.64) | 1.25 (1.11–1.41) | 1.24 (1.10–1.40) | 1.24 (1.10–1.40) |
| Quadruple lipids < median | < median | 539/1660 | REF | REF | REF | N/A |
| (n=3120) | ≥ median | 574/1460 | 1.49 (1.32–1.69) | 1.42 (1.24–1.63) | 1.41 (1.23–1.62) | N/A |
| Quadruple lipids ≥ median | < median | 479/1460 | REF | REF | REF | N/A |
| (n=3079) | ≥ median | 656/1619 | 1.45 (1.28–1.63) | 1.22 (1.07–1.40) | 1.22 (1.07–1.40) | N/A |

hsCRP less than median groups are reference. Triple lipids: LDL-C + non-HDL-C + apolipoprotein B. Quadruple lipids: LDL-C + non-HDL-C + apolipoprotein B + TC/HDL-C. Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apolipoprotein B: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L. Model 1: adjusted for age, sex, race/center. Model 2: Model 1 + physical activity + smoking status + body mass index + systolic blood pressure + treatment for hypertension + diabetes mellitus + lipid-lowering medication use. Model 3: Model 2 + log-triglycerides. Model 4: Model 3 + log-HDL-C. International System of Units conversion factors: To convert total, LDL-C, and HDL-C to mmol/L, multiply by 0.0249. To convert triglycerides to mmol/L, multiply by 0.0113. ARIC indicates Atherosclerosis Risk in Communities; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; N/A indicates not applicable; TC, total cholesterol.

Systematic Coronary Risk Evaluation risk but does not provide specific guidance to hsCRP targets or treatment strategies in patients with heightened inflammation.

We performed discordance analyses to approach the prognostic value of inflammation in primary prevention from a different angle. In our study, 1 in 2 individuals from ARIC had discordance between ≥1 atherogenic lipid measures and hsCRP, with associated increased ASCVD risk in fully adjusted models, which strengthens the evidence that hsCRP can

provide additional risk-modifying information in primary prevention beyond all lipid levels. This increased risk attributed to hsCRP remained consistent across categories of estimated risk by the PCE (*P*-interaction >0.05). Notably, individuals with hsCRP ≥2 mg/L compared with <2 mg/L had a 68% increased risk of ASCVD among individuals categorized as low risk by PCE (score <7.5%). Our findings add to the evidence that anti-inflammatory lifestyle and pharmacotherapeutic approaches may be considered in a precision-risk-

Table 6. Hazard Ratios (95%CI) for Coronary Death Across Concordant/Discordant Groups By Medians: The Atherosclerosis Risk in Communities Study

| Lipid Target Groups | hsCRP | Coronary deaths, n/Individuals, n | Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 3 HR (95% CI) | Model 4 HR (95% CI) |
|---------------------------|----------|-----------------------------------|---------------------|---------------------|---------------------|---------------------|
| Triple lipids < median | < median | 41/2060 | REF | REF | REF | REF |
| (n=3938) | ≥ median | 75/1878 | 2.55 (1.72–3.77) | 1.98 (1.29–3.05) | 1.98 (1.29–3.05) | 1.96 (1.27–3.02) |
| Triple lipids ≥ median | < median | 48/1954 | REF | REF | REF | REF |
| (n=4064) | ≥ median | 92/2110 | 2.25 (1.57–3.22) | 1.78 (1.20–2.65) | 1.76 (1.17–2.63) | 1.74 (1.16–2.60) |
| Quadruple lipids < median | < median | 27/1660 | REF | REF | REF | N/A |
| (n=3120) | ≥ median | 51/1460 | 2.84 (1.75–4.62) | 2.61 (1.54–4.42) | 2.62 (1.55–4.43) | N/A |
| Quadruple lipids ≥ median | < median | 41/1460 | REF | REF | REF | N/A |
| (n=3079) | ≥ median | 78/1619 | 2.17 (1.47–3.21) | 1.73 (1.13–2.65) | 1.73 (1.13–2.65) | N/A |

hsCRP less than median groups are reference. Triple lipids: LDL-C + non-HDL-C + apolipoprotein B. Quadruple lipids: LDL-C + non-HDL-C + apolipoprotein B + TC/HDL-C. Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apolipoprotein B: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L. Model 1: adjusted for age, sex, race/center. Model 2: Model 1 + physical activity + smoking status + body mass index + systolic blood pressure + treatment for hypertension + diabetes mellitus + lipid-lowering medication use. Model 3: Model 2 + log-triglycerides. Model 4: Model 3 + log-HDL-C. International System of Units conversion factors: To convert total, LDL-C, and HDL-C to mmol/L, multiply by 0.0249. To convert triglycerides to mmol/L, multiply by 0.0113. ARIC indicates Atherosclerosis Risk in Communities; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; N/A indicates not applicable; TC, total cholesterol.

Table 7. Hazard Ratios (95% CI) for ASCVD Events Across Concordant/Discordant Groups by JUPITER Cut Points: The ARIC Study

| Lipid Target Groups | hsCRP | ASCVD events, n/Individuals, n | Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 3 HR (95% CI) | Model 4 HR (95% CI) |
|------------------------------|---------|--------------------------------|---------------------|---------------------|---------------------|---------------------|
| Triple lipids < cut point | <2 mg/L | 252/2208 | REF | REF | REF | REF |
| (n=4709) | ≥2 mg/L | 398/2501 | 1.60 (1.36–1.89) | 1.45 (1.21–1.73) | 1.41 (1.18–1.68) | 1.40 (1.17–1.68) |
| Triple lipids ≥ cut point | <2 mg/L | 215/1294 | REF | REF | REF | REF |
| (n=3140) | ≥2 mg/L | 392/1846 | 1.46 (1.24–1.73) | 1.27 (1.06–1.54) | 1.27 (1.05–1.53) | 1.26 (1.04–1.52) |
| Quadruple lipids < cut point | <2 mg/L | 189/1797 | REF | REF | REF | N/A |
| (n=3765) | ≥2 mg/L | 279/1968 | 1.52 (1.25–1.84) | 1.43 (1.15–1.76) | 1.39 (1.12–1.72) | N/A |
| Quadruple lipids ≥ cut point | <2 mg/L | 172/1956 | REF | REF | REF | N/A |
| (n=3371) | ≥2 mg/L | 322/1415 | 1.45 (1.20–1.75) | 1.28 (1.04–1.58) | 1.28 (1.04–1.57) | N/A |

hsCRP <2 mg/L groups are reference. Triple lipids: LDL-C + non-HDL-C + apolipoprotein B. Quadruple lipids: LDL-C + non-HDL-C + apolipoprotein B + TC/HDL-C. Cut points: LDL-C: 130 mg/dL (percentile 57), non-HDL-C: 160 mg/dL, apolipoprotein B: 102 mg/dL, TC/HDL: 4.4, HDL-C: 50 mg/dL, hsCRP: 2 mg/L. Model 1: adjusted for age, sex, race/center. Model 2: Model 1 + physical activity + smoking status + body mass index + systolic blood pressure + treatment for hypertension + diabetes mellitus + lipid-lowering medication use. Model 3: Model 2 + log-triglycerides. Model 4: Model 3 + log-HDL-C. International System of Units conversion factors: To convert total, LDL-C, and HDL-C to mmol/L, multiply by 0.0249. To convert triglycerides to mmol/L, multiply by 0.0113. ARIC indicates Atherosclerosis Risk in Communities; ASCVD, atherosclerotic cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; JUPITER, Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; N/A indicates not applicable; TC, total cholesterol.

based approach in individuals with elevated hsCRP.²⁹ A recent study from MESA (Multi-Ethnic Study of Atherosclerosis) showed that moderate-to-vigorous physical activity was associated with a more favorable profile of inflammatory markers, possible attributable to reduction in central adiposity.³⁰ Similarly, dietary regimens such as the Mediterranean diet have been shown to improve markers of inflammation.³¹ In individuals with elevated hsCRP, reducing the lifelong burden of inflammation (a term we call *inflammation pack-years*) using lifestyle interventions or anti-inflammatory pharmacotherapies, such as high-intensity statin therapy, should be a cornerstone of primordial and primary prevention.

Implications for JUPITER-Like Population

The JUPITER trial increased the eligibility of adults for statin therapy in the United States and is the primary evidence behind the most recent guideline recommendations to use a hsCRP level of >2 mg/L as a risk enhancer in intermediate risk patients.³² However, Mora et al³³ showed that residual risk associated with elevated hsCRP in the JUPITER trial could be explained by a higher number of atherogenic particles other than LDL-C. Given the well-described discordance between LDL-C and other, more robust atherogenic lipid measures (ie, non-HDL-C or apolipoprotein B),⁹ we further refined the JUPITER population by sequentially adding atherogenic lipid cut points of percentile equivalence to LDL-C 130 mg/dL in order to fully assess the lipid-independent risk attributed to hsCRP. We found that after ≈18 years of follow-up (about 10-fold longer than median JUPITER follow-up), baseline hsCRP

≥2 mg/L was associated with a 32% to 37% increased risk of ASCVD as compared with hsCRP<2 mg/L among individuals with LDL-C <130 mg/dL and simultaneously more favorable levels of non-HDL-C (<160 mg/dL), apolipoprotein B (<102 mg/dL), TC/HDL-C ratio (<4.4), and HDL-C (≥50 mg/dL) combined. This increased independent risk was also independent of their global ASCVD risk assessed by the PCE score. We subsequently advanced these concepts by examining whether hsCRP ≥2 mg/L was associated with an increased risk of ASCVD when atherogenic lipid levels were as low as LDL-C <100 mg/dL, as recommended by some guidelines for high-risk patients, and percentile equivalent values of non-HDL-C, apolipoprotein B, and TC/HDL-C. The results were all consistent, suggesting that we ought to reemphasize the importance of using high-intensity statin therapy, as recommended by JUPITER, in individuals with hsCRP ≥2 mg/L regardless of their lipid levels or PCE risk score.

But is heightened inflammation, in primary prevention, also associated with other clinical outcomes over a long period of follow-up? We were able to show that hsCRP is consistently associated with the risk of incident HF and all-cause death, which suggests the possibility that inflammation reduction might have a broad favorable impact on several clinical outcomes, as proposed by other studies.^{25,34}

Strengths and Limitations

The present study has several important strengths. First, this is the longest primary prevention study to date (median follow-up, 18 years) that has examined the association of hsCRP with ASCVD events, and the first to perform an

individual-level discordance analysis to assess the additional prognostic information provided by hsCRP when discordant with LDL-C and other lipid measures. Second, we used several sets of cut points going from medians (to make our results easier to interpret), to clinical cut points for lipid measures and hsCRP based on observations from the JUPITER trial and recommended guideline targets for individuals at high risk. Third, because direct measurement of LDL-C by gold-standard ultra-centrifugation was not available in ARIC, we used a novel LDL-C estimation method that provides a more accurate estimation than the Friedewald equation.^{13,35} Finally, we demonstrated consistent results when doing time-sensitive analyses and when analyzing other outcomes such as HF incidence and all-cause death.

It is also important to acknowledge our limitations. This was an observational study and residual confounding may explain some of the associations seen. Discordance analyses are categorical by nature and do not allow for studying the predictive power of hsCRP as a continuous variable. However, discordance methods using clinically relevant biomarker cut points allow for personalized individual-level risk discrimination that is more in line with clinical practice and cholesterol treatment guidelines. Finally, this prospective analysis shows that hsCRP predicts ASCVD risk, incident HF, and all-cause death independent of all atherogenic lipoprotein levels, but it does not prove that inflammation is a direct cause of such events.

Conclusions

Discordance between hsCRP and atherogenic lipoproteins is prevalent ($\geq 50\%$). Long-term elevated hsCRP is associated with increased ASCVD risk, incident HF, and all-cause death even when all atherogenic lipids and HDL-C levels are more favorable and regardless of estimated PCE risk score. Future studies are needed to assess the use of hsCRP to identify individuals that might benefit from lifestyle and anti-inflammatory therapies to mitigate this risk.

Acknowledgments

The authors thank the staff and participants of the ARIC study for their important contributions.

Sources of Funding

The Atherosclerosis Risk in Communities study was funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under contract

numbers HHSN2682017000011, HHSN2682017000021, HHSN2682017000031, HHSN2682017000051, and HHSN2682017000041). The publication of this article was funded by the Weill Cornell Medicine – Qatar Distributed eLibrary.

Disclosures

Drs Martin and Jones are listed as coinventors on a pending patent filed by Johns Hopkins University for LDLn-C estimation. Dr Jones has served as an advisor to Sano/Regeneron. Dr Martin has served as a consultant to Quest Diagnostics, Sano/Regeneron, Amgen, and the Pew Research Center. Dr Puri has received speakers' fees from Sanofi-Aventis and Amgen and research honorarium from Cerenis (unrelated to the present work). Unrelated to this work, Dr. Michos received an honorarium from Siemens Healthcare for being a blinded adjudicator of events in a clinical trial. The remaining authors have no disclosures to report.

References

- Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. *Nature*. 2011;473:317–325.
- Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med*. 2002;347:1557–1565.
- Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med*. 2001;344:1959–1965.
- Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195–2207.
- Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tereshakovec AM, Blazing MA, Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in improve-it. *Circulation*. 2015;132:1224–1233.
- Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/L: an analysis of the prove-IT TIMI-22 trial. *J Am Coll Cardiol*. 2005;45:1644–1648.
- Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377:1119–1131.
- Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the cantos randomised controlled trial. *Lancet*. 2018;391:319–328.
- Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. *Circulation*. 2014;129:553–561.
- Elshazly MB, Nicholls SJ, Nissen SE, St John J, Martin SS, Jones SR, Quispe R, Stegman B, Kapadia SR, Tuzcu EM, Puri R. Implications of total to high-density lipoprotein cholesterol ratio discordance with alternative lipid parameters for coronary atheroma progression and cardiovascular events. *Am J Cardiol*. 2016;118:647–655.
- Quispe R, Elshazly MB, Zhao D, Toth PP, Puri R, Virani SS, Blumenthal RS, Martin SS, Jones SR, Michos ED. Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: the ARIC study. *Eur J Prev Cardiol*.

2019. DOI: <https://doi.org/10.1177/2047487319862401>. [Epub ahead of print].
12. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. The ARIC investigators. *Am J Epidemiol*. 1989;129:687–702.
 13. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. *JAMA*. 2013;310:2061–2068.
 14. Meeusen JW, Lueke AJ, Jaffe AS, Saenger AK. Validation of a proposed novel equation for estimating LDL cholesterol. *Clin Chem*. 2014;60:1519–1523.
 15. Lee J, Jang S, Son H. Validation of the Martin method for estimating low-density lipoprotein cholesterol levels in Korean adults: findings from the Korea national health and nutrition examination survey, 2009–2011. *PLoS One*. 2016;11:e0148147.
 16. Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceska R, Lopez-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Comparison of low-density lipoprotein cholesterol assessment by Martin/Hopkins estimation, Friedewald estimation, and preparative ultracentrifugation: insights from the Fourier trial. *JAMA Cardiol*. 2018;3:749–753.
 17. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglul L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS guidelines for the management of dyslipidaemias. *Eur Heart J*. 2016;37:2999–3058.
 18. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1—executive summary. *J Clin Lipidol*. 2014;8:473–488.
 19. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. *Stroke*. 1999;30:736–743.
 20. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). *Am J Cardiol*. 2008;101:1016–1022.
 21. White AD, Folsom AR, Chambless LE, Sharret AR, Yang K, Conwill D, Higgins M, Williams OD, Tyroler HA. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study: methods and initial two years' experience. *J Clin Epidemiol*. 1996;49:223–233.
 22. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. *Circulation*. 2014;129:S49–S73.
 23. Qureshi WT, Rana JS, Yeboah J, Bin Nasir U, Al-Mallah MH. Risk stratification for primary prevention of coronary artery disease: roles of C-reactive protein and coronary artery calcium. *Curr Cardiol Rep*. 2015;17:110.
 24. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. *JAMA*. 2012;308:788–795.
 25. Yeboah J, Young R, McClelland RL, Delaney JC, Polonsky TS, Dawood FZ, Blaha MJ, Miedema MD, Sibley CT, Carr JJ, Burke GL, Goff DC Jr, Psaty BM, Greenland P, Herrington DM. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. *J Am Coll Cardiol*. 2016;67:139–147.
 26. Cainzos-Achirica M, Miedema MD, McEvoy JW, Cushman M, Dardari Z, Greenland P, Nasir K, Budoff MJ, Al-Mallah MH, Yeboah J, Blumenthal RS, Comin-Colet J, Blaha MJ. The prognostic value of high sensitivity C-reactive protein in a multi-ethnic population after >10 years of follow-up: the Multi-Ethnic Study of Atherosclerosis (mesa). *Int J Cardiol*. 2018;264:158–164.
 27. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet*. 2010;375:132–140.
 28. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2019;139:e1082–e1143.
 29. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenland K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. *Circulation*. 2010;121:586–613.
 30. Vella CA, Allison MA, Cushman M, Jenny NS, Miles MP, Larsen B, Lakoski SG, Michos ED, Blaha MJ. Physical activity and adiposity-related inflammation: the MESA. *Med Sci Sports Exerc*. 2017;49:915–921.
 31. Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. *Am J Med*. 2015;128:229–238.
 32. Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. *J Am Coll Cardiol*. 2009;53:931–935.
 33. Mora S, Caulfield MP, Wohlgenuth J, Chen Z, Superko HR, Rowland CM, Glynn RJ, Ridker PM, Krauss RM. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. *Circulation*. 2015;132:2220–2229.
 34. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet*. 2017;390:1833–1842.
 35. Quispe R, Hendrani A, Elshazly MB, Michos ED, McEvoy JW, Blaha MJ, Banach M, Kulkarni KR, Toth PP, Coresh J, Blumenthal RS, Jones SR, Martin SS. Accuracy of low-density lipoprotein cholesterol estimation at very low levels. *BMC Med*. 2017;15:83.

SUPPLEMENTAL MATERIAL

Table S1. Hazard Ratios (95%CI) for ASCVD events across concordant/discordant groups by medians: the Atherosclerosis Risk in Communities Study (1996-2016).

| Lipid Target Groups | hsCRP | n ASCVD events/ n individuals | Model 1 HR (95%CI) | Model 2 HR (95%CI) | Model 3 HR (95%CI) | Model 4 HR (95%CI) |
|---|----------|----------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| LDL-C < median (n=4,797) | < median | 308/2,438 | REF | REF | REF | REF |
| | ≥ median | 379/2,359 | 1.49 (1.28-1.75) | 1.34 (1.13-1.59) | 1.29 (1.09-1.54) | 1.30 (1.09-1.54) |
| LDL-C ≥ median (n=4,951) | < median | 373/2,432 | REF | REF | REF | REF |
| | ≥ median | 514/2,519 | 1.58 (1.38-1.81) | 1.35 (1.16-1.58) | 1.33 (1.14-1.54) | 1.32 (1.13-1.53) |
| Dual lipids < median (n=4,445) | < median | 283/2,295 | REF | REF | REF | REF |
| | ≥ median | 340/2,150 | 1.50 (1.27-1.77) | 1.37 (1.14-1.65) | 1.33 (1.11-1.60) | 1.33 (1.11-1.60) |
| Dual lipids ≥ median (n=4,549) | < median | 350/2,211 | REF | REF | REF | REF |
| | ≥ median | 485/2,338 | 1.57 (1.37-1.81) | 1.38 (1.18-1.61) | 1.36 (1.16-1.60) | 1.35 (1.16-1.58) |
| Triple lipids < median (n=3,938) | < median | 237/2,060 | REF | REF | REF | REF |
| | ≥ median | 290/1,878 | 1.57 (1.31-1.88) | 1.46 (1.19-1.78) | 1.42 (1.16-1.74) | 1.42 (1.16-1.73) |
| Triple lipids ≥ median (n=4,064) | < median | 315/1,954 | REF | REF | REF | REF |
| | ≥ median | 442/2,110 | 1.56 (1.34-1.81) | 1.33 (1.13-1.57) | 1.32 (1.12-1.56) | 1.31 (1.11-1.55) |
| Quadruple lipids < median (n=3,120) | < median | 171/1,660 | REF | REF | REF | N/A |
| | ≥ median | 207/1,460 | 1.62 (1.31-2.01) | 1.60 (1.26-2.02) | 1.56 (1.23-1.98) | N/A |
| Quadruple lipids ≥ median (n=3,079) | < median | 257/1,460 | REF | REF | REF | N/A |
| | ≥ median | 362/1,619 | 1.52 (1.29-1.79) | 1.30 (1.08-1.56) | 1.29 (1.08-1.55) | N/A |
| Quadruple lipids < median + HDL-C ≥ median (n=2,971) | < median | 159/1,574 | REF | REF | REF | N/A |
| | ≥ median | 189/1,397 | 1.58 (1.26-1.97) | 1.59 (1.25-2.03) | 1.56 (1.22-1.99) | N/A |
| Quadruple lipids ≥ median + HDL-C < median (n=1,253) | < median | 116/557 | REF | REF | REF | N/A |
| | ≥ median | 174/696 | 1.43 (1.12-1.82) | 1.25 (0.96-1.64) | 1.26 (0.96-1.65) | N/A |

Dual lipids: LDL-C + non-HDL-C; Triple lipids: LDL-C + non-HDL-C + apoB. Quadruple lipids: LDL-C + non-HDL-C + apoB + TC/HDL-C

hsCRP <median groups are reference.

Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apoB: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L

Model 1: adjusted for age, sex, race/center

Model 2: Model 1 + physical activity + smoking status + BMI+ systolic blood pressure + treatment for hypertension + diabetes + lipid-lowering medication use

Model 3: Model 2 + log-triglycerides

Model 4: Model 3 + log-HDL-C.

N/A: Not applicable

SI conversion factors: To convert total, LDL-C and HDL-C to mmol/L, multiply by 0.0249. To convert triglycerides to mmol/L, multiply by 0.0113.

Table S2. Hazard Ratios (95%CI) for ASCVD events across concordant/discordant groups by risk categories in medians: the Atherosclerosis Risk in Communities Study (1996-2016).

| Lipid Target Groups | hsCRP | Low risk (<7.5%) | | High risk (≥7.5%) | |
|--|----------|----------------------------------|------------------|----------------------------------|------------------|
| | | n ASCVD events/ n individuals | HR (95%CI) | n ASCVD events/ n individuals | HR (95%CI) |
| LDL-C < median (n=4,797) | < median | 96/1,239 | REF | 208/1,175 | REF |
| | ≥ median | 156/1,254 | 1.70 (1.32-2.19) | 219/1,085 | 1.24 (1.02-1.49) |
| LDL-C ≥ median (n=4,951) | < median | 93/1,007 | REF | 277/1,406 | REF |
| | ≥ median | 155/1,113 | 1.58 (1.23-2.05) | 353/1,388 | 1.42 (1.21-1.67) |
| Dual lipids < median (n=4,445) | < median | 90/1,193 | REF | 190/1,080 | REF |
| | ≥ median | 143/1,162 | 1.72 (1.32-2.24) | 193/969 | 1.23 (1.01-1.51) |
| Dual lipids ≥ median (n=4,549) | < median | 86/887 | REF | 262/1,307 | REF |
| | ≥ median | 146/1,030 | 1.53 (1.17-2.00) | 335/1,294 | 1.44 (1.22-1.69) |
| Triple lipids < median (n=3,938) | < median | 80/1,091 | REF | 154/948 | REF |
| | ≥ median | 125/1,010 | 1.79 (1.35-2.37) | 162/851 | 1.27 (1.02-1.59) |
| Triple lipids ≥ median (n=4,064) | < median | 75/779 | REF | 238/1,162 | REF |
| | ≥ median | 134/931 | 1.57 (1.18-2.08) | 304/1,169 | 1.42 (1.20-1.69) |
| Quadruple lipids < median (n=3,120) | < median | 65/955 | REF | 104/688 | REF |
| | ≥ median | 96/857 | 1.73 (1.26-2.37) | 110/591 | 1.35 (1.03-1.77) |
| Quadruple lipids ≥ median (n=3,079) | < median | 56/507 | REF | 199/942 | REF |
| | ≥ median | 101/651 | 1.47 (1.06-2.04) | 258/962 | 1.42 (1.18-1.71) |
| Quadruple lipids <median + HDL-C ≥ median (n=2,971) | < median | 61/913 | REF | 96/644 | REF |
| | ≥ median | 89/835 | 1.67 (1.21-2.32) | 99/550 | 1.31 (0.99-1.74) |
| Quadruple lipids ≥median + HDL-C <median (n=1,253) | < median | 18/139 | REF | 96/413 | REF |
| | ≥ median | 45/243 | 1.51 (0.88-2.62) | 126/449 | 1.37 (1.05-1.79) |

Dual lipids: LDL-C + non-HDL-C; Triple lipids: LDL-C + non-HDL-C + apoB. Quadruple lipids: LDL-C + non-HDL-C + apoB + TC/HDL-C
hsCRP <median groups are reference.

Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apoB: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L

Models adjusted for lipid-lowering medication use

N/A: Not applicable

SI conversion factors: To convert total, LDL-C and HDL-C to mmol/L, multiple by 0.0249. To convert triglycerides to mmol/L, multiple by 0.0113

Table S3. Hazard Ratios (95%CI) for coronary death (competing risk) across concordant/discordant groups by medians: the Atherosclerosis Risk in Communities Study (1996-2016).

| Lipid Target Groups | hsCRP | n coronary deaths/ n individuals | Model 1 HR (95%CI) | Model 2 HR (95%CI) | Model 3 HR (95%CI) | Model 4 HR (95%CI) |
|--|----------|-------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Triple lipids < median (n=3,938) | < median | 41/2,060 | REF | REF | REF | REF |
| | ≥ median | 75/1,878 | 2.30 (1.56-3.39) | 1.82 (1.19-2.80) | 1.83 (1.19-2.80) | 1.81 (1.18-2.77) |
| Triple lipids ≥ median (n=4,064) | < median | 48/1,954 | REF | REF | REF | REF |
| | ≥ median | 92/2,110 | 2.00 (1.40-2.87) | 1.65 (1.11-2.46) | 1.63 (1.09-2.44) | 1.61 (1.08-2.42) |
| Quadruple lipids < median (n=3,120) | < median | 27/1,660 | REF | REF | REF | N/A |
| | ≥ median | 51/1,460 | 2.53 (1.57-4.06) | 2.30 (1.37-3.87) | 2.31 (1.37-3.88) | N/A |
| Quadruple lipids ≥ median (n=3,079) | < median | 41/1,460 | REF | REF | REF | N/A |
| | ≥ median | 78/1,619 | 1.91 (1.29-2.82) | 1.56 (1.03-2.37) | 1.56 (1.03-2.37) | N/A |

hsCRP <median groups are reference. Triple lipids: LDL-C + non-HDL-C + apoB. Quadruple lipids: LDL-C + non-HDL-C + apoB + TC/HDL-C

Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apoB: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L

Competing event: non-coronary death

Model 1: adjusted for age, sex, race/center

Model 2: Model 1 + physical activity + smoking status + BMI+ systolic blood pressure + treatment for hypertension + diabetes + lipid-lowering medication use

Model 3: Model 2 + log-triglycerides

Model 4: Model 3 + log-HDL-C.

N/A: Not applicable

SI conversion factors: To convert total, LDL-C and HDL-C to mmol/L, multiple by 0.0249. To convert triglycerides to mmol/L, multiple by 0.0113

Table S4. Hazard Ratios (95%CI) for ASCVD events across concordant/discordant groups by JUPITER cutpoints: the Atherosclerosis Risk in Communities Study (1996-2016).

| Lipid Target Groups | hsCRP | n ASCVD events/ n individuals | Model 1 HR (95%CI) | Model 2 HR (95%CI) | Model 3 HR (95%CI) | Model 4 HR (95%CI) |
|---|----------|----------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| LDL-C < cutpoint (n=5,623) | < 2 mg/L | 313/2,547 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 508/3,076 | 1.58 (1.36-1.83) | 1.41 (1.21-1.66) | 1.37 (1.17-1.61) | 1.37 (1.16-1.61) |
| LDL -C ≥ cutpoint (n=4,125) | < 2 mg/L | 277/1,766 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 476/2,359 | 1.48 (1.27-1.72) | 1.30 (1.10-1.53) | 1.28 (1.08-1.51) | 1.27 (1.07-1.50) |
| Dual lipids < cutpoint (n=5,367) | < 2 mg/L | 300/2,450 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 476/2,917 | 1.56 (1.34-1.81) | 1.41 (1.19-1.66) | 1.36 (1.15-1.61) | 1.36 (1.15-1.60) |
| Dual lipids ≥ cutpoint (n=3,483) | < 2 mg/L | 239/1,447 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 425/2,036 | 1.45 (1.23-1.70) | 1.28 (1.07-1.53) | 1.27 (1.06-1.52) | 1.26 (1.05-1.51) |
| Triple lipids < cutpoint (n=4,709) | < 2 mg/L | 252/2,208 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 398/2,501 | 1.60 (1.36-1.89) | 1.45 (1.21-1.73) | 1.41 (1.18-1.68) | 1.40 (1.17-1.68) |
| Triple lipids ≥ cutpoint (n=3,140) | < 2 mg/L | 215/1,294 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 392/1,846 | 1.46 (1.24-1.73) | 1.27 (1.06-1.54) | 1.27 (1.05-1.53) | 1.26 (1.04-1.52) |
| Quadruple lipids < cutpoint (n=3,765) | < 2 mg/L | 189/1,797 | REF | REF | REF | N/A |
| | ≥ 2 mg/L | 279/1,968 | 1.52 (1.25-1.84) | 1.43 (1.15-1.76) | 1.39 (1.12-1.72) | N/A |
| Quadruple lipids ≥ cutpoint (n=3,371) | < 2 mg/L | 172/1,956 | REF | REF | REF | N/A |
| | ≥ 2 mg/L | 322/1,415 | 1.45 (1.20-1.75) | 1.28 (1.04-1.58) | 1.28 (1.04-1.57) | N/A |
| Quadruple lipids < cutpoint + HDL-C ≥ cutpoint (n=2,552) | < 2 mg/L | 127/1,252 | REF | REF | REF | N/A |
| | ≥ 2 mg/L | 163/1,300 | 1.40 (1.10-1.79) | 1.42 (1.09-1.86) | 1.37 (1.02-1.80) | N/A |
| Quadruple lipids ≥ cutpoint + HDL-C < cutpoint (n=2,027) | < 2 mg/L | 148/789 | REF | REF | REF | N/A |
| | ≥ 2 mg/L | 290/1,238 | 1.46 (1.19-1.78) | 1.30 (1.04-1.62) | 1.26 (1.04-1.62) | N/A |

Dual lipids: LDL-C + non-HDL-C; Triple lipids: LDL-C + non-HDL-C + apoB. Quadruple lipids: LDL-C + non-HDL-C + apoB + TC/HDL-C

hsCRP <2 mg/L groups are reference.

Cutpoints: LDL-C: 130 mg/dL (percentile 57), non-HDL-C: 160 mg/dL, apoB: 102 mg/dL, TC/HDL: 4.4, HDL-C: 50 mg/dL, hsCRP: 2 mg/L

Model 1: adjusted for age, sex, race/center

Model 2: Model 1 + physical activity + smoking status + BMI+ systolic blood pressure + treatment for hypertension + diabetes + lipid-lowering medication use

Model 3: Model 2 + log-triglycerides

Model 4: Model 3 + log-HDL-C.

N/A: Not applicable

SI conversion factors: To convert total, LDL-C and HDL-C to mmol/L, multiple by 0.0249. To convert triglycerides to mmol/L, multiple by 0.0113.

Table S5. Hazard Ratios (95%CI) for ASCVD events across concordant/discordant groups by JUPITER cutpoints and hsCRP categories: the Atherosclerosis Risk in Communities Study (1996-2016).

| Lipid Target Groups | hsCRP | n ASCVD events/ n individuals | Model 1 HR (95%CI) | Model 2 HR (95%CI) | Model 3 HR (95%CI) | Model 4 HR (95%CI) |
|---|--------------|----------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| LDL-C < cutpoint (n=5,623) | <1 mg/L | 154/1,375 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 159/1,172 | 1.22 (0.98-1.53) | 1.18 (0.93-1.50) | 1.14 (0.90-1.44) | 1.13 (0.89-1.43) |
| | 2 to <3 mg/L | 105/664 | 1.54 (1.20-1.97) | 1.42 (1.09-1.85) | 1.36 (1.04-1.78) | 1.35 (1.03-1.76) |
| | ≥3 mg/L | 403/2,412 | 1.81 (1.50-2.20) | 1.59 (1.28-1.97) | 1.51 (1.21-1.87) | 1.50 (1.21-1.86) |
| LDL -C ≥ cutpoint (n=4,125) | <1 mg/L | 122/858 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 155/908 | 1.24 (0.97-1.57) | 1.15 (0.89-1.47) | 1.13 (0.88-1.46) | 1.12 (0.87-1.44) |
| | 2 to <3 mg/L | 89/563 | 1.15 (0.87-1.51) | 1.12 (0.84-1.49) | 1.10 (0.83-1.47) | 1.09 (0.82-1.46) |
| | ≥3 mg/L | 386/1,795 | 1.86 (1.51-2.29) | 1.51 (1.20-1.91) | 1.48 (1.17-1.87) | 1.46 (1.15-1.84) |
| Dual lipids < cutpoint (n=5,367) | <1 mg/L | 145/1,336 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 155/1,114 | 1.29 (1.03-1.62) | 1.26 (0.99-1.60) | 1.20 (0.94-1.54) | 1.20 (0.94-1.52) |
| | 2 to <3 mg/L | 99/632 | 1.56 (1.21-2.02) | 1.44 (1.10-1.90) | 1.38 (1.05-1.83) | 1.37 (1.04-1.81) |
| | ≥3 mg/L | 377/2,285 | 1.84 (1.51-2.24) | 1.64 (1.31-2.04) | 1.55 (1.24-1.93) | 1.54 (1.23-1.93) |
| Dual lipids ≥ cutpoint (n=3,483) | <1 mg/L | 107/683 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 132/764 | 1.14 (0.88-1.47) | 1.08 (0.82-1.41) | 1.07 (0.82-1.40) | 1.06 (0.81-1.39) |
| | 2 to <3 mg/L | 78/470 | 1.10 (0.82-1.48) | 1.06 (0.78-1.44) | 1.05 (0.77-1.43) | 1.04 (0.76-1.42) |
| | ≥3 mg/L | 346/1,565 | 1.71 (1.38-2.14) | 1.44 (1.13-1.83) | 1.42 (1.11-1.82) | 1.40 (1.10-1.79) |
| Triple lipids < cutpoint (n=4,709) | <1 mg/L | 126/1,228 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 126/980 | 1.29 (1.01-1.65) | 1.24 (0.95-1.61) | 1.19 (0.92-1.55) | 1.18 (0.91-1.54) |
| | 2 to <3 mg/L | 89/551 | 1.71 (1.30-2.24) | 1.55 (1.15-2.08) | 1.49 (1.11-2.00) | 1.48 (1.10-1.99) |

| | | | | | | |
|---|--------------|-----------|------------------|------------------|------------------|------------------|
| | ≥3 mg/L | 309/1,950 | 1.84 (1.49-2.28) | 1.64 (1.29-2.08) | 1.56 (1.23-1.98) | 1.55 (1.22-1.97) |
| Triple lipids ≥ cutpoint (n=3,140) | <1 mg/L | 98/610 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 117/684 | 1.11 (0.84-1.45) | 1.05 (0.79-1.40) | 1.05 (0.79-1.39) | 1.04 (0.78-1.38) |
| | 2 to <3 mg/L | 74/426 | 1.12 (0.83-1.52) | 1.06 (0.77-1.47) | 1.06 (0.77-1.46) | 1.05 (0.76-1.45) |
| | ≥3 mg/L | 317/1,419 | 1.70 (1.35-2.14) | 1.41 (1.09-1.81) | 1.39 (1.08-1.80) | 1.37 (1.06-1.78) |
| Quadruple lipids < cutpoint (n=3,765) | <1 mg/L | 100/1,035 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 89/762 | 1.26 (0.94-1.70) | 1.23 (0.91-1.67) | 1.20 (0.88-1.63) | N/A |
| | 2 to <3 mg/L | 55/417 | 1.48 (1.06-2.06) | 1.36 (0.95-1.96) | 1.32 (0.92-1.90) | N/A |
| | ≥3 mg/L | 224/1,551 | 1.75 (1.37-2.24) | 1.66 (1.26-2.18) | 1.60 (1.21-2.10) | N/A |
| Quadruple lipids ≥ cutpoint (n=3,371) | <1 mg/L | 77/439 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 95/517 | 1.09 (0.81-1.47) | 1.05 (0.76-1.44) | 1.04 (0.76-1.43) | N/A |
| | 2 to <3 mg/L | 66/329 | 1.18 (0.85-1.64) | 1.15 (0.81-1.63) | 1.14 (0.81-1.62) | N/A |
| | ≥3 mg/L | 255/1,085 | 1.65 (1.27-2.13) | 1.38 (1.04-1.84) | 1.37 (1.03-1.83) | N/A |
| Quadruple lipids < cutpoint + HDL-C ≥ cutpoint (n=2,552) | <1 mg/L | 72/753 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 55/499 | 1.25 (0.88-1.79) | 1.29 (0.88-1.89) | 1.25 (0.85-1.83) | N/A |
| | 2 to <3 mg/L | 35/267 | 1.56 (1.04-2.34) | 1.53 (0.99-2.37) | 1.48 (0.95-2.30) | N/A |
| | ≥3 mg/L | 128/1,033 | 1.54 (1.13-2.09) | 1.62 (1.15-2.28) | 1.53 (1.08-2.17) | N/A |
| Quadruple lipids ≥ cutpoint + HDL-C < cutpoint (n=2,027) | <1 mg/L | 66/361 | REF | REF | REF | REF |
| | 1 to <2 mg/L | 82/428 | 1.08 (0.78-1.49) | 1.05 (0.74-1.48) | 1.05 (0.74-1.48) | N/A |
| | 2 to <3 mg/L | 60/290 | 1.17 (0.83-1.67) | 1.14 (0.79-1.65) | 1.14 (0.79-1.65) | N/A |
| | ≥3 mg/L | 229/947 | 1.65 (1.25-2.18) | 1.41 (1.04-1.92) | 1.41 (1.03-1.91) | N/A |

Dual lipids: LDL-C + non-HDL-C; Triple lipids: LDL-C + non-HDL-C + apoB. Quadruple lipids: LDL-C + non-HDL-C + apoB + TC/HDL-C

hsCRP <1 mg/L is reference group

Cutpoints: LDL-C: 130 mg/dL (percentile 57), non-HDL-C: 160 mg/dL, apoB: 102 mg/dL, TC/HDL: 4.4, HDL-C: 50 mg/dL, hsCRP: 2 mg/L

Model 1: adjusted for age, sex, race/center

Model 2: Model 1 + physical activity + smoking status + BMI+ systolic blood pressure + treatment for hypertension + diabetes + lipid-lowering medication use

Model 3: Model 2 + log-triglycerides

Model 4: Model 3 + log-HDL-C

N/A: Not applicable

SI conversion factors: To convert total, LDL-C and HDL-C to mmol/L, multiple by 0.0249. To convert triglycerides to mmol/L, multiple by 0.0113.

Table S6. Hazard Ratios (95%CI) for ASCVD events across concordant/discordant groups by high-risk cutpoints: the Atherosclerosis Risk in Communities Study (1996-2016).

| Lipid Target Groups | hsCRP | n ASCVD events/ n individuals | Model 1 HR (95%CI) | Model 2 HR (95%CI) | Model 3 HR (95%CI) | Model 4 HR (95%CI) |
|---|----------|----------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| LDL-C < cutpoint (n=2,066) | < 2 mg/L | 114/962 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 163/1,104 | 1.41 (1.10-1.81) | 1.41 (1.06-1.86) | 1.35 (1.02-1.79) | 1.35 (1.02-1.79) |
| LDL -C ≥ cutpoint (n=7,682) | < 2 mg/L | 476/3,351 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 821/4,331 | 1.57 (1.40-1.76) | 1.35 (1.19-1.54) | 1.32 (1.16-1.50) | 1.31 (1.15-1.49) |
| Dual lipids < cutpoint (n=1,957) | < 2 mg/L | 109/924 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 151/1,033 | 1.39 (1.08-1.80) | 1.42 (1.07-1.90) | 1.35 (1.01-1.81) | 1.36 (1.01-1.81) |
| Dual lipids ≥ cutpoint (n=6,811) | < 2 mg/L | 429/2,902 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 752/3,909 | 1.53 (1.35-1.73) | 1.33 (1.16-1.52) | 1.29 (1.13-1.48) | 1.29 (1.13-1.47) |
| Triple lipids < cutpoint (n=1,489) | < 2 mg/L | 86/731 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 118/758 | 1.50 (1.12-2.00) | 1.52 (1.10-2.10) | 1.45 (1.05-2.01) | 1.45 (1.05-2.01) |
| Triple lipids ≥ cutpoint (n=6,624) | < 2 mg/L | 417/2,820 | REF | REF | REF | REF |
| | ≥ 2 mg/L | 730/3,804 | 1.53 (1.35-1.73) | 1.35 (1.18-1.55) | 1.32 (1.15-1.51) | 1.31 (1.14-1.50) |
| Quadruple lipids < cutpoint (n=976) | < 2 mg/L | 55/500 | REF | REF | REF | N/A |
| | ≥ 2 mg/L | 65/476 | 1.40 (0.96-2.04) | 1.49 (0.98-2.25) | 1.44 (0.95-2.19) | N/A |
| Quadruple lipids ≥ cutpoint (n=6,200) | < 2 mg/L | 403/2,612 | REF | REF | REF | N/A |
| | ≥ 2 mg/L | 703/3,588 | 1.48 (1.30-1.67) | 1.32 (1.15-1.51) | 1.29 (1.12-1.48) | N/A |
| Quadruple lipids < cutpoint + HDL-C ≥ cutpoint (n=907) | < 2 mg/L | 52/469 | REF | REF | REF | N/A |
| | ≥ 2 mg/L | 56/438 | 1.29 (0.87-1.91) | 1.32 (0.86-2.04) | 1.30 (0.84-2.01) | N/A |
| Quadruple lipids ≥ cutpoint + HDL-C < cutpoint (n=4,017) | < 2 mg/L | 281/1,652 | REF | REF | REF | N/A |
| | ≥ 2 mg/L | 515/2,365 | 1.48 (1.28-1.72) | 1.34 (1.14-1.58) | 1.33 (1.13-1.56) | N/A |

Dual lipids: LDL-C + non-HDL-C; Triple lipids: LDL-C + non-HDL-C + apoB. Quadruple lipids: LDL-C + non-HDL-C + apoB + TC/HDL-C

hsCRP <2 mg/L groups are reference.

Cutpoints: LDL-C: 100 mg/dL (percentile 21), non-HDL-C: 130 mg/dL, apoB: 80 mg/dL, TC/HDL: 3.1, HDL-C: 50 mg/dL, hsCRP: 2 mg/L

Model 1: adjusted for age, sex, race/center

Model 2: Model 1 + physical activity + smoking status + BMI+ systolic blood pressure + treatment for hypertension + diabetes + lipid-lowering medication use

Model 3: Model 2 + log-triglycerides

Model 4: Model 3 + log-HDL-C.

N/A: Not applicable

SI conversion factors: To convert total, LDL-C and HDL-C to mmol/L, multiple by 0.0249. To convert triglycerides to mmol/L, multiple by 0.0113

Table S7. Time-Varying Hazard Ratios (95%CI) for ASCVD events across concordant/discordant groups by medians: the Atherosclerosis Risk in Communities Study (1996-2016).

| Lipid Target Groups | hsCRP | n ASCVD events/ n individuals | Model 1 HR (95%CI) | Model 2 HR (95%CI) | Model 3 HR (95%CI) | Model 4 HR (95%CI) |
|---|----------|----------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| LDL-C < median (n=4,797) | < median | 308/2,438 | REF | REF | REF | REF |
| | ≥ median | 379/2,359 | 1.48 (1.26-1.73) | 1.40 (1.17-1.66) | 1.37 (1.15-1.64) | 1.37 (1.15-1.64) |
| LDL-C ≥ median (n=4,951) | < median | 373/2,432 | REF | REF | REF | REF |
| | ≥ median | 514/2,519 | 1.43 (1.25-1.65) | 1.30 (1.11-1.51) | 1.27 (1.09-1.49) | 1.27 (1.09-1.49) |
| Dual lipids < median (n=4,445) | < median | 283/2,295 | REF | REF | REF | REF |
| | ≥ median | 340/2,150 | 1.44 (1.22-1.70) | 1.39 (1.16-1.67) | 1.37 (1.14-1.65) | 1.37 (1.14-1.65) |
| Dual lipids ≥ median (n=4,549) | < median | 350/2,211 | REF | REF | REF | REF |
| | ≥ median | 485/2,338 | 1.46 (1.27-1.69) | 1.36 (1.16-1.59) | 1.34 (1.15-1.58) | 1.34 (1.15-1.58) |
| Triple lipids < median (n=3,938) | < median | 237/2,060 | REF | REF | REF | REF |
| | ≥ median | 290/1,878 | 1.54 (1.29-1.85) | 1.45 (1.18-1.77) | 1.44 (1.18-1.76) | 1.44 (1.18-1.76) |
| Triple lipids ≥ median (n=4,064) | < median | 315/1,954 | REF | REF | REF | REF |
| | ≥ median | 442/2,110 | 1.42 (1.23-1.65) | 1.29 (1.09-1.52) | 1.28 (1.08-1.51) | 1.28 (1.08-1.51) |
| Quadruple lipids < median (n=3,120) | < median | 171/1,660 | REF | REF | REF | N/A |
| | ≥ median | 207/1,460 | 1.50 (1.21-1.86) | 1.48 (1.16-1.88) | 1.47 (1.15-1.87) | N/A |
| Quadruple lipids ≥ median (n=3,079) | < median | 257/1,460 | REF | REF | REF | N/A |
| | ≥ median | 362/1,619 | 1.36 (1.16-1.61) | 1.19 (0.99-1.43) | 1.19 (0.99-1.43) | N/A |
| Quadruple lipids < median + HDL-C ≥ median (n=2,971) | < median | 159/1,574 | REF | REF | REF | N/A |
| | ≥ median | 189/1,397 | 1.45 (1.16-1.82) | 1.47 (1.15-1.89) | 1.46 (1.13-1.87) | N/A |
| Quadruple lipids ≥ median + HDL-C < median (n=1,253) | < median | 116/557 | REF | REF | REF | N/A |
| | ≥ median | 174/696 | 1.29 (1.01-1.64) | 1.11 (0.85-1.47) | 1.12 (0.85-1.48) | N/A |

Dual lipids: LDL-C + non-HDL-C; Triple lipids: LDL-C + non-HDL-C + apoB. Quadruple lipids: LDL-C + non-HDL-C + apoB + TC/HDL-C
hsCRP <median groups are reference.

Medians: LDL-C: 123 mg/dL, non-HDL-C: 149 mg/dL, apoB: 98 mg/dL, TC/HDL: 4.2, HDL-C: 40 mg/dL, hsCRP: 2.4 mg/L

Model 1: adjusted for age, sex, race/center

Model 2: Model 1 + physical activity + smoking status (time-varying) + BMI (time-varying) + systolic blood pressure (time-varying) + treatment for hypertension (time-varying) + diabetes (time-varying) + lipid-lowering medications use (time-varying)

Model 3: Model 2 + log-triglycerides

Model 4: Model 3 + log-HDL-C.

N/A: Not applicable

SI conversion factors: To convert total, LDL-C and HDL-C to mmol/L, multiple by 0.0249. To convert triglycerides to mmol/L, multiple by 0.0113.

Figure S1. Proportions of hsCRP > and ≤median in single, dual, triple, quadruple and quintuple lipid group < and ≥median.




Figure S2. Proportions of hsCRP > and ≤2mg/L in single, dual, triple, quadruple and quintuple lipid groups < and ≥JUPITER cutpoints.




Figure S3. Kaplan-Meier curves for event-free survival of incident heart failure by hsCRP < and \geq median among individuals with triple (A), quadruple (B) lipid measures < median (left) and \geq median (right)




Figure S4. Kaplan-Meier curves for event-free survival of total mortality by hsCRP < and \geq median among individuals with triple (A), quadruple (B) lipid measures < median (left) and \geq median (right)

